PROF
Profound Medical
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
MACD Golden Cross
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About PROF
Profound Medical Corp.
A commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue
Healthcare Equipment and Supplies
07/16/2014
10/29/2019
NASDAQ Stock Exchange
142
12-31
Common stock
2400 Skymark Avenue
, Unit 6
, Mississauga
, Ontario L4W 5K5
--
Profound Medical Corp. and its subsidiaries were established on July 16, 2014 under the Ontario Business Corporations Act. The company is a medical technology company that develops fusion prostate, uterine fibroids and nerve treatments to reduce palliative pain in patients with metastatic bone disease.
Company Financials
EPS
PROF has released its 2024 Q4 earnings. EPS was reported at 0.20, versus the expected -0.32, beating expectations. The chart below visualizes how PROF has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PROF has released its 2024 Q4 earnings report, with revenue of 3.71M, reflecting a YoY change of 84.42%, and net profit of -5.33M, showing a YoY change of 38.43%. The Sankey diagram below clearly presents PROF’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
